FACULTY
Improving Outcomes In Alzheimer's Disease: The Role Of The Pharmacist
Part Three: Caring for the Caregiver
Activity Date: November 2005  — Activity Info: Volume 2, (7)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity

 

Full Disclosure Policy Affecting CE Activities:
As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:

PROGRAM DIRECTOR

W. Nathan Rawls, PharmD
Clinical Pharmacy Specialist
Veterans Affairs Medical Center
Professor, Department of Pharmacy
University of Tennessee College of Pharmacy
Memphis, Tennessee
Dr Rawls reports having no financial or advisory relationships with corporate organizations related to this activity.

PARTICIPATING FACULTY

Manju Beier, PharmD, FASCP
President, Geriatric Consultant Resources LLC
Clinical Associate Professor of Pharmacy
University of Michigan School of Pharmacy
Ann Arbor, Michigan
Dr Beier reports serving as a consultant for Forest Laboratories, Janssen Pharmaceutica, and Pfizer Inc; and receiving honoraria from Bristol-Myers Squibb Company, Forest Laboratories, Janssen Pharmaceutica, and Pfizer Inc.

Diane Crutchfield, PharmD, CGP, FASCP
President, Pharmacy Consulting Care
Knoxville, Tennessee
Dr Crutchfield reports serving on the speaker’s bureau for AstraZeneca, Forest Laboratories, Ortho-Biotech, and Pfizer Inc.

Jeanne Jackson-Siegal, MD
Assistant Clinical Professor of Psychiatry
Yale University School of Medicine
Medical Director
Alzheimer's Resource Center
New Haven, Connecticut
Dr Jackson-Siegal reports receiving grants/research support from Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, and Voyager Pharmaceuticals; serving as a consultant for Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Forest Laboratories, and Pfizer Inc; and serving on the speaker’s bureau for Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Organon, and Pfizer Inc.

Notice: In accordance with the ACPE Criteria for Quality, the audience is advised that articles in this continuing pharmaceutical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.

Dr Beier—cholinesterase inhibitors for moderate to severe Alzheimer’s disease, and memantine for mild to moderate Alzheimer’s disease.
Dr Jackson-Siegal—trazodone, all atypical agents (olanzapine, risperidone, quetiapine, aripiprazole, and ziprasidone), mood stabilizers (valproic acid, carbamazepine, lamotrigine, and gabapentin), and haloperidol.
All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?